ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
IPO Year: 1985
Exchange: NASDAQ
Website: acadia-pharm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2026 | $29.00 | Neutral → Buy | BofA Securities |
| 2/24/2026 | $33.00 | Outperform | Wolfe Research |
| 2/23/2026 | $35.00 | Neutral → Outperform | Mizuho |
| 10/21/2025 | $33.00 | Buy | Citigroup |
| 5/21/2025 | $35.00 | Hold → Buy | Deutsche Bank |
| 2/11/2025 | $22.00 | Hold | Deutsche Bank |
| 1/3/2025 | $23.00 → $20.00 | Buy → Neutral | Guggenheim |
| 10/10/2024 | Mkt Perform | Raymond James | |
| 8/7/2024 | $28.00 → $20.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/27/2024 | $31.00 | Outperform | BMO Capital Markets |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BofA Securities upgraded ACADIA Pharmaceuticals from Neutral to Buy and set a new price target of $29.00
Wolfe Research initiated coverage of ACADIA Pharmaceuticals with a rating of Outperform and set a new price target of $33.00
Mizuho upgraded ACADIA Pharmaceuticals from Neutral to Outperform and set a new price target of $35.00
Citigroup initiated coverage of ACADIA Pharmaceuticals with a rating of Buy and set a new price target of $33.00
Deutsche Bank upgraded ACADIA Pharmaceuticals from Hold to Buy and set a new price target of $35.00
Deutsche Bank initiated coverage of ACADIA Pharmaceuticals with a rating of Hold and set a new price target of $22.00
Guggenheim downgraded ACADIA Pharmaceuticals from Buy to Neutral and set a new price target of $20.00 from $23.00 previously
Raymond James resumed coverage of ACADIA Pharmaceuticals with a rating of Mkt Perform
Morgan Stanley downgraded ACADIA Pharmaceuticals from Overweight to Equal-Weight and set a new price target of $20.00 from $28.00 previously
BMO Capital Markets initiated coverage of ACADIA Pharmaceuticals with a rating of Outperform and set a new price target of $31.00
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
10-Q - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
DEF 14A - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
SCHEDULE 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
SCHEDULE 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-16) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 05/04/2026. Application Category: NDA, Application Number: 210793, Application Classification: Labeling
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-16) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 04/27/2026. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-14) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 04/27/2026. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity
Fastest customizable press release news feed in the world
- First quarter DAYBUE® GAAP net sales of $101 million, up 20% year-over-year; successful launch of DAYBUE STIX underway - First quarter NUPLAZID® GAAP net sales of $167 million, up 6% year-over-year on a non-GAAP adjusted basis - Reaffirms expectation for topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis between August and October 2026 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), today announced its financial results for the first quarter ended March 31, 2026. "Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million," said Catherine Owen Adams, C
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and leadership continuity through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer's disease psychosis (ADP) and into early Phase 3 clinical study execution. Acadia has initiated a search for a new He
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at two upcoming investor conferences: BofA Securities 2026 Health Care Conference Fireside Chat: Tuesday, May 12, 2026 at 4:20 p.m. Pacific Time in Las Vegas, NV 2026 RBC Capital Markets Global Healthcare Conference Fireside Chat: Tuesday, May 19, 2026 at 9:00 a.m. Eastern Time in New York, NY Live webcasts will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful i
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL. The Company will present real-world data from a sub-group analysis of the ongoing, Phase 4, prospective, observational, open-label LOTUS study evaluating the benefits and tolerability of DAYBUE® (trofinetide) in adults with Rett syndrome in routine clinical practice. In support of NUPLAZID® (pimavanserin) in Parkinson's disease psychosis (PDP), Acadia will present exploratory analyses evaluating heterogeneity in treatment response trajectories
Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in numb
-- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for Rett syndrome and highlights the importance of flexible, patient-centered treatment approaches Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration (FDA) in December 2025, is bioequivalent to the original DAYBUE
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:00 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and onl
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally adopted a negative opinion regarding the Marketing Authorization Application for trofinetide for the treatment of Rett syndrome in patients two years of age and older. Acadia has reviewed the CHMP grounds for refusal in detail and intends to request a re-examination of the opinion. While the pivotal LAVENDERTM trial successfully met its co-primary and key secondary endpoints, the CHMP issued a refusal based on perceived deficits including: the treatment effect observed with trofinetide after 12
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA The Citizens Life Sciences Conference Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL Live webcasts will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is committed to turning scientific promise into meaningful innovati
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
Live Leadership Updates
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons and informed Acadia of her plans. She will continue in her role as Head of Research and Development until a successor is appointed. After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and leadership continuity through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer's disease psychosis (ADP) and into early Phase 3 clinical study execution. Acadia has initiated a search for a new He
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Konstantina ("Tina") Katcheves as Senior Vice President, Chief Business and Strategy Officer. In this role, Tina will lead Acadia's business development and corporate strategy and serve as a member of the Company's Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia. "Tina brings a wealth of experience in global business development and strategic partnerships that will be instrumental as we continue to expand our pipeline and pursue high-impact growth opportunities," said Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals. "Her leadership and deep i
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott will lead Acadia's digital transformation including technology, data and AI strategy and will serve as a member of the company's Executive Leadership Team, reporting to Catherine Owen Adams, Chief Executive Officer of Acadia. "We are thrilled to welcome Scott to Acadia," said Catherine Owen Adams. "Scott's extensive leadership in digital transformation, AI-driven innovation, and global IT operations across leading biopharmaceutical companies makes him an ideal fit for our organization. His proven ability to scale digital
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia's commercial leadership team with a focus on maximizing the potential of DAYBUE® and preparing for future product launches as the Company expands its rare disease portfolio. "We are delighted to welcome Allyson to Acadia," said Catherine Owen Adams, Chief Executive Officer. "She brings a remarkable breadth of experience across U.S. and global sales and marketing roles, with a proven track record of delivering strong commercial results. Her leadership across therapeutic areas—including oncology
NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Jan 3, 2025 S&P SmallCap 600 Addition Acadia Pharmaceuticals ACAD Health Care Jan 3, 2025 S&P SmallCap 600 Deletion Independent Bank Group
– Seasoned commercial executive with more than 25 years pharmaceutical and biotech experience Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia's CEO, and serve on the executive leadership team. "Tom is an accomplished commercial executive with a demonstrated history of driving brand growth across a wide range of therapeutic areas
- Ms. Owen Adams brings over 25 years of pharmaceutical industry experience including senior commercial leadership roles with Bristol Myers Squibb and Johnson & Johnson Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. "We are excited to welcome Catherine Owen Adams as the new CEO of Acadia," said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. "Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical industry. Her strategic vision, deep expertise, and unwavering
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company's Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia. "Liz is a preeminent drug research and development leader with extensive experience in the advancement and commercialization of first in class therapies," said Steve Davis, Chief Executive Officer. "Her passion and expertise for developing new medicines that address areas of high unmet need will be a huge asset to Acadia and an important add
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company's Executive Management Committee. He will report to Mark Schneyer, Executive Vice President, Chief Financial Officer of Acadia. "Al brings to Acadia a strong track record of leading investor relations and corporate communications functions at numerous growth-oriented companies across the healthcare industry," said Mark Schneyer, Executive Vice President, Chief Financial Officer. "His deep experienc
Live finance-specific insights
- First quarter DAYBUE® GAAP net sales of $101 million, up 20% year-over-year; successful launch of DAYBUE STIX underway - First quarter NUPLAZID® GAAP net sales of $167 million, up 6% year-over-year on a non-GAAP adjusted basis - Reaffirms expectation for topline results from the Phase 2 remlifanserin study in Alzheimer's disease psychosis between August and October 2026 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), today announced its financial results for the first quarter ended March 31, 2026. "Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales of $101 million," said Catherine Owen Adams, C
Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in numb
Company to host conference call and webcast on Wednesday, February 25, 2026, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 25, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until May 24, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive
- Third quarter total revenues of $278.6 million, up 11% year-over-year - Narrowing and raising high end of NUPLAZID® net product sales guidance to $685 to $695 million - Updating DAYBUE® net product sales guidance to $385 to $400 million Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the third quarter ended September 30, 2025. "Acadia delivered another strong quarter, generating total revenue of $278.6 million," said Catherine Owen Adams, Chief Executive Officer. "NUPLAZID achieved record sales of $177.5 million representing a significant inflection driven by an acceleration in new prescriptions. DAYBUE delivered $101.1 million in sales, driven by t
Company to host conference call and webcast on Wednesday, November 5, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 5, 2025, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until February 5, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with
- Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID® (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE® (trofinetide) net product sales of $96.1 million, up 14% year-over-year - Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance - Top-line results expected for COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the second quarter ended June 30, 2025. "Acadia continued to build momentum in the second qua
Company to host conference call and webcast on Wednesday, August 6, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report second quarter financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 6, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until November 5, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number
- First quarter total revenues of $244.3 million, up 19% year-over-year - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year - First quarter DAYBUE® (trofinetide) net product sales of $84.6 million, up 11% year-over-year, and up 9.5% in unique patients shipped - Reiterates full year 2025 revenue guidance including DAYBUE net sales of $380 to $405 million and NUPLAZID net sales of $650 to $690 million - Accelerated timing for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome, topline results now expected in early Q4 2025 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the first quarter ended M
Company to host conference call and webcast on Wednesday, May 7, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report first quarter financial results on Wednesday, May 7, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 7, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until August 6, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PI
- 2024 total net product sales of $957.8 million, reflecting 32% revenue growth - Fourth quarter DAYBUE® (trofinetide) net product sales of $96.7 million and full year 2024 net product sales of $348.4 million - Fourth quarter NUPLAZID® (pimavanserin) net product sales of $162.9 million and full year 2024 net product sales of $609.4 million - Full year 2025 total revenue guidance of $1.03 to $1.095 billion including DAYBUE net sales guidance of $380 to $405 million and NUPLAZID net sales guidance of $650 to $690 million Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a s
This live feed shows all institutional transactions in real time.
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13D/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13D/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)